# Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy

> **NCT06490068** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 10 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** LTC004+Toripalimab

## Key facts

- **NCT ID:** NCT06490068
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-04
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06490068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06490068, "Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06490068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*